BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 30150259)

  • 1. Oral Immunization with Nontoxigenic Clostridium difficile Strains Expressing Chimeric Fragments of TcdA and TcdB Elicits Protective Immunity against C. difficile Infection in Both Mice and Hamsters.
    Wang Y; Wang S; Bouillaut L; Li C; Duan Z; Zhang K; Ju X; Tzipori S; Sonenshein AL; Sun X
    Infect Immun; 2018 Nov; 86(11):. PubMed ID: 30150259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A chimeric protein comprising the glucosyltransferase and cysteine proteinase domains of toxin B and the receptor binding domain of toxin A induces protective immunity against Clostridium difficile infection in mice and hamsters.
    Wang YK; Yan YX; Kim HB; Ju X; Zhao S; Zhang K; Tzipori S; Sun X
    Hum Vaccin Immunother; 2015; 11(9):2215-22. PubMed ID: 26036797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of an Effective Nontoxigenic Clostridioides difficile-Based Oral Vaccine against C. difficile Infection.
    Wang S; Zhu D; Sun X
    Microbiol Spectr; 2022 Jun; 10(3):e0026322. PubMed ID: 35583336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clostridium difficile chimeric toxin receptor binding domain vaccine induced protection against different strains in active and passive challenge models.
    Tian JH; Glenn G; Flyer D; Zhou B; Liu Y; Sullivan E; Wu H; Cummings JF; Elllingsworth L; Smith G
    Vaccine; 2017 Jul; 35(33):4079-4087. PubMed ID: 28669616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel fusion protein containing the receptor binding domains of C. difficile toxin A and toxin B elicits protective immunity against lethal toxin and spore challenge in preclinical efficacy models.
    Tian JH; Fuhrmann SR; Kluepfel-Stahl S; Carman RJ; Ellingsworth L; Flyer DC
    Vaccine; 2012 Jun; 30(28):4249-58. PubMed ID: 22537987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic and Phenotypic Characterization of the Nontoxigenic Clostridioides difficile Strain CCUG37785 and Demonstration of Its Therapeutic Potential for the Prevention of C. difficile Infection.
    Wang S; Heuler J; Wickramage I; Sun X
    Microbiol Spectr; 2022 Apr; 10(2):e0178821. PubMed ID: 35315695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The recombinant Lactococcus lactis oral vaccine induces protection against C. difficile spore challenge in a mouse model.
    Guo S; Yan W; McDonough SP; Lin N; Wu KJ; He H; Xiang H; Yang M; Moreira MA; Chang YF
    Vaccine; 2015 Mar; 33(13):1586-95. PubMed ID: 25698490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic antibody responses induced by a two-component Clostridium difficile toxoid vaccine protect against C. difficile-associated disease in hamsters.
    Anosova NG; Brown AM; Li L; Liu N; Cole LE; Zhang J; Mehta H; Kleanthous H
    J Med Microbiol; 2013 Sep; 62(Pt 9):1394-1404. PubMed ID: 23518659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toll-like receptor 5-dependent immunogenicity and protective efficacy of a recombinant fusion protein vaccine containing the nontoxic domains of Clostridium difficile toxins A and B and Salmonella enterica serovar typhimurium flagellin in a mouse model of Clostridium difficile disease.
    Ghose C; Verhagen JM; Chen X; Yu J; Huang Y; Chenesseau O; Kelly CP; Ho DD
    Infect Immun; 2013 Jun; 81(6):2190-6. PubMed ID: 23545305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a recombinant toxin fragment vaccine for Clostridium difficile infection.
    Karczewski J; Zorman J; Wang S; Miezeiewski M; Xie J; Soring K; Petrescu I; Rogers I; Thiriot DS; Cook JC; Chamberlin M; Xoconostle RF; Nahas DD; Joyce JG; Bodmer JL; Heinrichs JH; Secore S
    Vaccine; 2014 May; 32(24):2812-8. PubMed ID: 24662701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant lipoprotein-based vaccine candidates against C. difficile infections.
    Huang JH; Wu CW; Lien SP; Leng CH; Hsiao KN; Liu SJ; Chen HW; Siu LK; Chong P
    J Biomed Sci; 2015 Aug; 22(1):65. PubMed ID: 26245825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A chimeric toxin vaccine protects against primary and recurrent Clostridium difficile infection.
    Wang H; Sun X; Zhang Y; Li S; Chen K; Shi L; Nie W; Kumar R; Tzipori S; Wang J; Savidge T; Feng H
    Infect Immun; 2012 Aug; 80(8):2678-88. PubMed ID: 22615245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A DNA vaccine targeting TcdA and TcdB induces protective immunity against Clostridium difficile.
    Zhang BZ; Cai J; Yu B; Hua Y; Lau CC; Kao RY; Sze KH; Yuen KY; Huang JD
    BMC Infect Dis; 2016 Oct; 16(1):596. PubMed ID: 27770789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel approach to generate a recombinant toxoid vaccine against Clostridium difficile.
    Donald RGK; Flint M; Kalyan N; Johnson E; Witko SE; Kotash C; Zhao P; Megati S; Yurgelonis I; Lee PK; Matsuka YV; Severina E; Deatly A; Sidhu M; Jansen KU; Minton NP; Anderson AS
    Microbiology (Reading); 2013 Jul; 159(Pt 7):1254-1266. PubMed ID: 23629868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An optimized, synthetic DNA vaccine encoding the toxin A and toxin B receptor binding domains of Clostridium difficile induces protective antibody responses in vivo.
    Baliban SM; Michael A; Shammassian B; Mudakha S; Khan AS; Cocklin S; Zentner I; Latimer BP; Bouillaut L; Hunter M; Marx P; Sardesai NY; Welles SL; Jacobson JM; Weiner DB; Kutzler MA
    Infect Immun; 2014 Oct; 82(10):4080-91. PubMed ID: 25024365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination against
    Winter K; Xing L; Kassardjian A; Ward BJ
    Infect Immun; 2019 Aug; 87(8):. PubMed ID: 31138615
    [No Abstract]   [Full Text] [Related]  

  • 17. Clostridium difficile Toxoid Vaccine Candidate Confers Broad Protection against a Range of Prevalent Circulating Strains in a Nonclinical Setting.
    Quemeneur L; Petiot N; Arnaud-Barbe N; Hessler C; Pietrobon PJ; Londoño-Hayes P
    Infect Immun; 2018 Jun; 86(6):. PubMed ID: 29632249
    [No Abstract]   [Full Text] [Related]  

  • 18. Novel Chimeric Protein Vaccines Against
    Wang S; Wang Y; Cai Y; Kelly CP; Sun X
    Front Immunol; 2018; 9():2440. PubMed ID: 30405630
    [No Abstract]   [Full Text] [Related]  

  • 19. Recombinant Clostridium difficile toxin fragments as carrier protein for PSII surface polysaccharide preserve their neutralizing activity.
    Romano MR; Leuzzi R; Cappelletti E; Tontini M; Nilo A; Proietti D; Berti F; Costantino P; Adamo R; Scarselli M
    Toxins (Basel); 2014 Apr; 6(4):1385-96. PubMed ID: 24759173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The protective effect of recombinant Lactococcus lactis oral vaccine on a Clostridium difficile-infected animal model.
    Yang XQ; Zhao YG; Chen XQ; Jiang B; Sun DY
    BMC Gastroenterol; 2013 Jul; 13():117. PubMed ID: 23865596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.